Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.17 |
|---|---|
| High | 2.40 |
| Low | 2.17 |
| Bid | 2.27 |
| Offer | 2.28 |
| Previous close | 2.14 |
| Average volume | 1.51m |
|---|---|
| Shares outstanding | 69.21m |
| Free float | 69.06m |
| P/E (TTM) | -- |
| Market cap | 148.11m USD |
| EPS (TTM) | -0.8839 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 20:55 GMT.
More ▼
Announcements
- Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
- Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
- Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System
- Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
- Nanox Announces $15 Million Registered Direct Offering of Common Stock
- Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update
- Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
- Nanox Announces Strategic Partnership with 3DR® Labs to Expand AI-Powered Imaging Solutions Across North America
- Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe
- Nanox to Launch FDA-Cleared Nanox.ARC X and Present development of new AI innovations at RSNA 2025 Annual Meeting
More ▼
